ArticleBMC cancer2025
The nasopharyngeal carcinoma in Xiamen China from 2011 to 2020: a population-based linkage study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasopharyngeal carcinoma (NPC) is not common in most parts of the world but is particularly prevalent in southern China. This study analyzed NPC incidence, mortality, years of life lost (YLL), and survival rates in Xiamen from 2011 to 2020.
methodsThis study mainly utilized data from the Xiamen City Cancer Registry, and cancer follow-up cohort, covering the period from 2011 to 2020. Crude and age-standardized incidence, mortality, YLL, and survival rates, as well as their trends were analyzed using annual percent change (APC) and average annual percent change (AAPC), stratified by sex and residency status.
resultsFrom 2011 to 2020, Xiamen reported 996 new NPC cases (733 males, 263 females) and 513 deaths (396 males, 117 females). Age-standardized incidence, mortality, and YLL rates were 3.58/100,000, 1.83/100,000, and 65.10/100,000, respectively. The AAPC in incidence and mortality rates of NPC was − 5.48% (95% CI: −9.25, −1.54, P < 0.05) and − 0.82% (95% CI: −6.01, 4.65, P > 0.05), respectively. The 5-year age-standardized relative survival rate was 55.98% (95%CI: 52.08, 60.17).
conclusionOver the recent decade, a consistent decline in the incidence of NPC has been observed, accompanied an insignificant decreasing mortality trend in Xiamen. Future efforts could focus on enhancing prevention, screening, and treatment strategies to potentially reinforcing these positive trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.